Dr. Ruane is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5901 W Olympic Blvd
Suite 401
Los Angeles, CA 90036Phone+1 323-954-1072Fax+1 323-954-1081
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Infectious Disease, 1984 - 1987
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1981 - 1984
University College of Dublin National Univ SOMClass of 1978
Certifications & Licensure
CA State Medical License 1986 - 2025
MN State Medical License 1983 - 1986- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2013
Clinical Trials
- Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current Treatment Start of enrollment: 2008 Mar 01
- Observational Registry Study of Quality of Life When Treating BTcP With Abstral Start of enrollment: 2013 Oct 01
- Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus Infection Start of enrollment: 2014 Oct 01
Publications & Presentations
PubMed
- 1 citationsHIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-lab...David A Wohl, Christoph D Spinner, Jason Flamm, C Bradley Hare, Susanne Doblecki-Lewis
The Lancet. HIV. 2024-08-01 - Dolutegravir/Lamivudine Efficacy and Safety Outcomes in People With HIV-1 With or Without Historical Resistance Results at Screening: 48-Week Pooled Analysis.Stefan Scholten, Pedro Cahn, Joaquín Portilla, Fiona Bisshop, Sally Hodder
Open Forum Infectious Diseases. 2024-07-01 - 8 citationsSafety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study.Joseph J Eron, Susan J Little, Gordon Crofoot, Paul Cook, Peter J Ruane
The Lancet. HIV. 2024-03-01
Press Mentions
Descovy for PrEP Remains Safe and Effective at 96 WeeksNovember 21st, 2019
Gilead Demonstrates Non-Inferiority of Descovy to Truvada for HIV PrEPNovember 7th, 2019
Gilead Presents 96-Week Discover Trial Data Supporting Non-Inferior Efficacy and Key Safety Differences of Descovy for PrEP™ Compared with Truvada for PrEP®November 6th, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
